![]() | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H23NO2 |
| Molar mass | 345.442 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Crisnatol (BW-A770U) is an experimental anticancer agent.[1] A Phase I clinical trial was published in 1999.[2]
References
- ↑ U.S. Patent 4,719,046
- ↑ Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, et al. (November 1999). "A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies". Clinical Cancer Research. 5 (11): 3369–78. PMID 10589747.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
